MarketPeel
Insider Trading Intelligence
Pricing
…
UW

Uri Weinberg

NVCR
CHIEF SCIENCE OFFICER · NOVOCURE LTD · CIK 0001811030
FILING MIX · LIFETIME53%/47%
BUYS
29
SELLS
26
TOTAL VALUE
$17.25M
COMPANIES
1
ACTIVE SINCE
May 2020
HOLDINGS NOW
267,190
AVG SELL PX
$88.27
TRADE KIND
SHOWING 55 / 55
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
17 backtested trades · 8 horizons · 12 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Uri Weinberg, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d17+70.59%-6.06%+0.55%-6.61%-3.33%—
14d17+58.82%-5.65%+0.34%-5.98%-6.67%—
30d17+64.71%-2.72%+1.43%-4.15%-0.98%—
60d17+47.06%-0.32%+4.45%-4.77%+2.34%—
90d17+41.18%+5.63%+6.83%-6.18%-7.81%—
180d17(3 pending)+85.71%-32.25%+14.53%-46.78%-46.70%—
1y17(3 pending)+85.71%-48.12%+18.58%-66.70%-59.90%—
2y17(6 pending)+100.00%-59.55%+26.14%-85.69%-63.17%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NVCR · 267,190 shares · as of Mar 4, 2026
068,401136,801205,202273,602202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 29 buys / 26 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NVCR
NOVOCURE LTD
SALE
Chf Medical and Innovation Ofr
6,412$13.31$85.3K267,190Mar 4, 2026Mar 5, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
73,340——73,340Mar 3, 2026Mar 5, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
50,125——273,602Mar 3, 2026Mar 5, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
Chf Medical and Innovation Ofr
3,272$13.33$43.6K223,477Mar 2, 2026Mar 3, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
12,992——226,749Feb 28, 2026Mar 3, 2026 ↗View →
NVCR
NOVOCURE LTD
SALE
Chf Medical and Innovation Ofr
7,461$13.84$103.3K213,757Feb 27, 2026Mar 3, 2026 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
54,975$18.19$1000.0K221,218Mar 4, 2025Mar 6, 2025 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
81,499$18.19$1.48M81,499Mar 4, 2025Mar 6, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Innovation Officer
268$18.92$5.1K166,243Mar 3, 2025Mar 4, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Innovation Officer
311$18.31$5.7K166,511Feb 28, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Innovation Officer
4,326$18.78$81.3K166,822Feb 28, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Innovation Officer
311$18.31$5.7K166,511Feb 28, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Innovation Officer
4,326$18.78$81.3K166,822Feb 28, 2025Mar 3, 2025 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
81,799$16.30$1.33M171,148Feb 27, 2024Feb 29, 2024 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
125,078$16.30$2.04M125,078Feb 27, 2024Feb 29, 2024 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
3,936——89,044Mar 3, 2023Mar 6, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
28,830——85,108Mar 3, 2023Mar 6, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
21,607$76.97$1.66M21,607Feb 28, 2023Mar 2, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
12,992——56,278Feb 28, 2023Mar 2, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
1,946$120.00$233.5K47,104Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
1,201$120.00$144.1K43,286Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
2,617$108.00$282.6K44,487Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
1,946$47.04$91.5K49,050Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
1,946——1,946Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
2,379$120.00$285.5K47,104Jan 5, 2023Jan 9, 2023 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
281$59.08$16.6K49,483Jul 5, 2022Jul 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
17,371——49,186Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
30,422$80.59$2.45M30,422Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
4,961$80.59$399.8K4,961Mar 3, 2022Mar 7, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
35$63.82$2.2K31,815Jan 6, 2022Jan 12, 2022 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
113$137.12$15.5K31,780Jul 6, 2021Jul 8, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
3,846$189.65$729.4K33,471May 10, 2021May 12, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
3,846——3,845May 10, 2021May 12, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
3,846$47.56$182.9K37,317May 10, 2021May 12, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
1,804$189.65$342.1K31,667May 10, 2021May 12, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
2,835$140.00$396.9K33,471Mar 23, 2021Apr 9, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
3,892$47.04$183.1K40,198Mar 23, 2021Mar 25, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
3,892$140.00$544.9K36,306Mar 23, 2021Mar 25, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
3,892——3,892Mar 23, 2021Mar 25, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
8,709——36,306Mar 2, 2021Mar 4, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
16,003——16,003Mar 2, 2021Mar 4, 2021 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
6,500$7.15$46.5K34,097Feb 22, 2021Feb 24, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
6,500$175.50$1.14M27,597Feb 22, 2021Feb 24, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
6,500——0Feb 22, 2021Feb 24, 2021 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
6,500$103.35$671.8K27,597Sep 25, 2020Sep 28, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
8,750$11.46$100.3K36,347Sep 25, 2020Sep 28, 2020 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
8,750$103.35$904.3K27,597Sep 25, 2020Sep 28, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
6,500$7.15$46.5K34,097Sep 25, 2020Sep 28, 2020 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
8,750——0Sep 25, 2020Sep 28, 2020 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
6,500——6,500Sep 25, 2020Sep 28, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
1,968——27,597Sep 1, 2020Sep 3, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
3,779——3,779Sep 1, 2020Sep 3, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASEGRANT
Stock grant
325$50.41$16.4K30,357Jul 7, 2020Jul 8, 2020 ↗View →
NVCR
NOVOCURE LTD
PURCHASE
Chief Science Officer
1,402$63.84$89.5K25,629May 8, 2020May 11, 2020 ↗View →
NVCR
NOVOCURE LTD
SALE
Chief Science Officer
1,402——2,803May 8, 2020May 11, 2020 ↗View →
Other insiders · NVCR
Loading peer insiders…
About this filer
CIK 0001811030
ROLE
Chief Science Officer
PRIMARY
NVCR
COMPANIES
1
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001811030DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback